Oracle Corp. shares soared on Wednesday after the company reported third-quarter results surpassing analyst expectations, with revenues of $17.19 billion and adjusted earnings of $1.79 per share. Oracle projects 18% to 20% revenue growth for the fourth quarter and new earnings estimates between $1.96 and $2.00 per share. The spotlight also shone on Oracle’s new Clinical AI tool, aimed at automating hospital documentation, which has shown efficiency gains in U.S. emergency departments. The Oracle Health Clinical AI Agent, already proven to reduce documentation time by 41%, has saved healthcare providers over 200,000 hours since its launch. With the stock trading 8.5% above its 20-day simple moving average and demonstrating a bullish trend, analysts maintain a Buy Rating with an average price target of $251.64. As Oracle prepares for its June 10, 2026 financial update, investor interest and activity remain robust.
Source link
